CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$40.19+0.04 (+0.10%)
Close on Nov 18, 2026Market cap $3.89BP/E –Yield –
CRISPR Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
CRISPR Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$534.34M. For fiscal 2025 it was -$664.57M. The highest annual figure on record is $373.53M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$664.57M | – |
| FY2024 | Dec 31, 2024 | -$466.57M | – |
| FY2023 | Dec 31, 2023 | -$222.54M | – |
| FY2022 | Dec 31, 2022 | -$673.16M | -280.2% |
| FY2021 | Dec 31, 2021 | $373.53M | – |
| FY2020 | Dec 31, 2020 | -$354.44M | -858.3% |
| FY2019 | Dec 31, 2019 | $46.74M | – |
| FY2018 | Dec 31, 2018 | -$158.94M | – |
| FY2017 | Dec 31, 2017 | -$64.65M | – |
| FY2016 | Dec 31, 2016 | -$68.13M | – |
| FY2015 | Dec 31, 2015 | -$25.73M | – |
| FY2014 | Dec 31, 2014 | -$6.63M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$117.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$130.25M | – |
| Q4 FY2025 | Dec 31, 2025 | -$154.76M | – |
| Q3 FY2025 | Sep 30, 2025 | -$132.06M | – |
| Q2 FY2025 | Jun 30, 2025 | -$229.32M | – |
| Q1 FY2025 | Mar 31, 2025 | -$148.42M | – |
| Q4 FY2024 | Dec 31, 2024 | -$64.59M | -192.8% |
| Q3 FY2024 | Sep 30, 2024 | -$110.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$151.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$140.59M | – |
| Q4 FY2023 | Dec 31, 2023 | $69.58M | – |
| Q3 FY2023 | Sep 30, 2023 | -$132.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -$95.22M | – |
| Q1 FY2023 | Mar 31, 2023 | -$64.49M | – |
| Q4 FY2022 | Dec 31, 2022 | -$131.54M | – |
| Q3 FY2022 | Sep 30, 2022 | -$182.39M | – |
| Q2 FY2022 | Jun 30, 2022 | -$183.26M | -124.0% |
| Q1 FY2022 | Mar 31, 2022 | -$175.97M | – |
| Q4 FY2021 | Dec 31, 2021 | -$145.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$128.85M | – |
| Q2 FY2021 | Jun 30, 2021 | $762.62M | – |
| Q1 FY2021 | Mar 31, 2021 | -$114.54M | – |
| Q4 FY2020 | Dec 31, 2020 | -$107.76M | -1081.2% |
| Q3 FY2020 | Sep 30, 2020 | -$92.40M | -166.4% |
| Q2 FY2020 | Jun 30, 2020 | -$80.69M | – |
| Q1 FY2020 | Mar 31, 2020 | -$73.59M | – |
| Q4 FY2019 | Dec 31, 2019 | $10.98M | – |
| Q3 FY2019 | Sep 30, 2019 | $139.16M | – |
| Q2 FY2019 | Jun 30, 2019 | -$54.98M | – |
| Q1 FY2019 | Mar 31, 2019 | -$48.42M | – |
| Q4 FY2018 | Dec 31, 2018 | -$45.23M | -4753.1% |
| Q3 FY2018 | Sep 30, 2018 | -$49.43M | – |
| Q2 FY2018 | Jun 30, 2018 | -$37.29M | – |
| Q1 FY2018 | Mar 31, 2018 | -$27.00M | – |
| Q4 FY2017 | Dec 31, 2017 | $972.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$23.57M | – |
| Q2 FY2017 | Jun 30, 2017 | -$21.31M | – |
| Q1 FY2017 | Mar 31, 2017 | -$20.74M | – |
| Q4 FY2016 | Dec 31, 2016 | -$25.31M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.61M | – |
See a number that looks wrong?